1. Home
  2. KPTI vs GLU Comparison

KPTI vs GLU Comparison

Compare KPTI & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • GLU
  • Stock Information
  • Founded
  • KPTI 2008
  • GLU 2004
  • Country
  • KPTI United States
  • GLU United States
  • Employees
  • KPTI 325
  • GLU N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • GLU Finance/Investors Services
  • Sector
  • KPTI Health Care
  • GLU Finance
  • Exchange
  • KPTI Nasdaq
  • GLU Nasdaq
  • Market Cap
  • KPTI 81.1M
  • GLU 92.2M
  • IPO Year
  • KPTI 2013
  • GLU N/A
  • Fundamental
  • Price
  • KPTI $0.66
  • GLU $15.65
  • Analyst Decision
  • KPTI Strong Buy
  • GLU
  • Analyst Count
  • KPTI 4
  • GLU 0
  • Target Price
  • KPTI $5.00
  • GLU N/A
  • AVG Volume (30 Days)
  • KPTI 671.2K
  • GLU 12.4K
  • Earning Date
  • KPTI 02-27-2025
  • GLU 01-01-0001
  • Dividend Yield
  • KPTI N/A
  • GLU 8.60%
  • EPS Growth
  • KPTI N/A
  • GLU N/A
  • EPS
  • KPTI N/A
  • GLU 0.62
  • Revenue
  • KPTI $148,442,000.00
  • GLU N/A
  • Revenue This Year
  • KPTI $5.47
  • GLU N/A
  • Revenue Next Year
  • KPTI $6.33
  • GLU N/A
  • P/E Ratio
  • KPTI N/A
  • GLU $22.50
  • Revenue Growth
  • KPTI 1.77
  • GLU N/A
  • 52 Week Low
  • KPTI $0.58
  • GLU $11.61
  • 52 Week High
  • KPTI $1.70
  • GLU $15.40
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 46.51
  • GLU 57.11
  • Support Level
  • KPTI $0.60
  • GLU $15.40
  • Resistance Level
  • KPTI $0.70
  • GLU $15.68
  • Average True Range (ATR)
  • KPTI 0.05
  • GLU 0.31
  • MACD
  • KPTI -0.00
  • GLU 0.10
  • Stochastic Oscillator
  • KPTI 46.61
  • GLU 86.79

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

Share on Social Networks: